- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lytix Biopharma AS (LYTIX)
Lytix Biopharma AS stock price live, this page displays OL LYTIX stock exchange data. View the LYTIX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lytix Biopharma AS real time stock price chart below.
What Is the Lytix Biopharma AS Stock Price Today?
The Lytix Biopharma AS stock price today is 9.38.
What Is the Stock Symbol for Lytix Biopharma AS?
The stock symbol for Lytix Biopharma AS is ""LYTIX.""
What Stock Exchange Does Lytix Biopharma AS Trade On?
Lytix Biopharma AS is listed and trades on the Oslo stock exchange.
Is Lytix Biopharma AS a Good Stock to Buy?
Determining whether Lytix Biopharma AS—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LYTIX quote. (ISIN: NO0010405780)
What Is the Lytix Biopharma AS Stock Price Today?
The Lytix Biopharma AS stock price today is 9.38.
What Is the Stock Symbol for Lytix Biopharma AS?
The stock symbol for Lytix Biopharma AS is ""LYTIX.""
What Stock Exchange Does Lytix Biopharma AS Trade On?
Lytix Biopharma AS is listed and trades on the Oslo stock exchange.
Is Lytix Biopharma AS a Good Stock to Buy?
Determining whether Lytix Biopharma AS—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LYTIX quote. (ISIN: NO0010405780)
Oslo
Currency in NOK
9.38
+0.52(+5.87%)
Closed·
Fair Value
An estimate of a Lytix Biopharma AS's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.52
9.68
52 wk Range
4.55
15.00
LYTIX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
LYTIX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Lytix Biopharma AS's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.529.68
52 wk Range
4.5515.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LYTIX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Lytix Biopharma AS's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock price often moves in the opposite direction of the market
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Lytix Biopharma AS Company Profile
Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of LTX-315 for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma AS was founded in 2003 and is based in Oslo, Norway.
Lytix Biopharma AS Earnings Call Summary for Q1/2025
- Lytix Biopharma's stock surged 17.78% to $7.42 after Q1 2025 earnings call, reflecting positive market sentiment
- Cash position increased to $118 million from $26 million YoY, with potential milestone payments of $110 million from Verica
- Promising results reported for lead candidate LTX-315 in melanoma and basal cell carcinoma studies
- Key milestones set for 2025-2026, including Phase II/III results and initiation of new trials, with cash runway extending into 2026
- CEO highlighted transition to commercial phase, emphasizing innovative dual-action approach to cancer treatment
Last Updated: 15/05/2025, 11:06
Read Full TranscriptCompare LYTIX to Peers and Sector
Metrics to compare | LYTIX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLYTIXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.2x | −3.4x | −0.5x | |
PEG Ratio | - | 0.01 | 0.00 | |
Price/Book | 6.7x | 2.6x | 2.6x | |
Price / LTM Sales | 1,053.1x | 8.9x | 3.3x | |
Upside (Analyst Target) | 38.6% | 48.8% | 43.4% | |
Fair Value Upside | Unlock | 13.9% | 7.1% | Unlock |
Earnings
Latest Release
Apr 10, 2025
EPS / Forecast
-0.54 / -1.20
Revenue / Forecast
377.00K / 1.60M
FAQ
What Stock Exchange Does Lytix Biopharma AS Trade On?
Lytix Biopharma AS is listed and trades on the Oslo Stock Exchange stock exchange.
What Is the Stock Symbol for Lytix Biopharma AS?
The stock symbol for Lytix Biopharma AS is "LYTIX."
What Is the Lytix Biopharma AS Market Cap?
As of today, Lytix Biopharma AS market cap is 640.30M.
What Is Lytix Biopharma AS's Earnings Per Share (TTM)?
The Lytix Biopharma AS EPS (TTM) is 0.00.
From a Technical Analysis Perspective, Is LYTIX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Lytix Biopharma AS Stock Split?
Lytix Biopharma AS has split 0 times.
How Many Employees Does Lytix Biopharma AS Have?
Lytix Biopharma AS has 8 employees.
What is the current trading status of Lytix Biopharma AS (LYTIX)?
As of 10 Aug 2025, Lytix Biopharma AS (LYTIX) is trading at a price of 9.38, with a previous close of 8.86. The stock has fluctuated within a day range of 8.52 to 9.68, while its 52-week range spans from 4.55 to 15.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.